Stock analysts at StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Down 15.7 %
NASDAQ:PIRS opened at $13.60 on Thursday. The company has a market cap of $17.95 million, a P/E ratio of -1.12 and a beta of 0.61. The firm’s 50 day moving average is $15.59 and its two-hundred day moving average is $14.84. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.
Institutional Trading of Pieris Pharmaceuticals
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. acquired a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned 1.21% of Pieris Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 40.11% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Read More
- Five stocks we like better than Pieris Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- What Do S&P 500 Stocks Tell Investors About the Market?
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
